Torrent Pharmaceuticals announced that Pranav Mehta, Executive Director (Strategic Planning) designated as Senior Management Personnel of the Company has tendered his resignation effective from close of business hours on 26 February 2025.Powered by Capital Market - Live News

Net profit of Torrent Pharmaceuticals rose 13.54% to Rs 503.00 crore in the quarter ended December 2024 as against Rs 443.00 crore during the previous quarter ended December 2023. Sales rose 2.64% to Rs 2762.00 crore in the quarter ended December 2024 as against Rs 2691.00 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales2762.002691.00 3 OPM %33.0932.29 - PBDT890.00756.00 18 PBT691.00543.00 27 NP503.00443.00 14 Powered by Capital Market - Live News

Torrent Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 24 January 2025, inter alia, have recommended the interim dividend of Rs 26 per equity Share (i.e. 520%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Torrent Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 24 January 2025.Powered by Capital Market - Live News

Net profit of Torrent Pharmaceuticals rose 17.36% to Rs 453.00 crore in the quarter ended September 2024 as against Rs 386.00 crore during the previous quarter ended September 2023. Sales rose 7.72% to Rs 2831.00 crore in the quarter ended September 2024 as against Rs 2628.00 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales2831.002628.00 8 OPM %33.1731.39 - PBDT859.00760.00 13 PBT661.00559.00 18 NP453.00386.00 17 Powered by Capital Market - Live News